Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease

PLoS Pathogens

Volumn 11, Issue 1, 2015, Pages 1-6

  Boursier, Jerome ^a,b   Diehl, Anna Mae ^c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b HIFIH UPRES 3859 SFR 4208 Université LUNAM   (France)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SHORT CHAIN FATTY ACID;

BACTERIAL OVERGROWTH; DISEASE ASSOCIATION; DYSBIOSIS; ENVIRONMENTAL FACTOR; HEPATITIS; HOMEOSTASIS; HUMAN; INTESTINE FLORA; LIPID DIET; LIVER CANCER; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHENOTYPE; REVIEW; RISK FACTOR; ADULT; ANIMAL; C57BL MOUSE; CHILD; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; INTESTINE; MICROBIOLOGY; MICROFLORA; MOUSE; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; ANIMALS; CHILD; COHORT STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; INTESTINES; MICE; MICE, INBRED C57BL; MICROBIOTA; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84923849535     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004559     Document Type: Review

References (30)

1. Wiest R, Garcia-Tsao G, (2005) Bacterial translocation (BT) in cirrhosis. Hepatology 41: 422–433. doi: 10.1002/hep.20632 15723320
2. Weinstock GM, (2012) Genomic approaches to studying the human microbiota. Nature 489: 250–256. doi: 10.1038/nature11553 22972298
3. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, et al. (2012) Host-gut microbiota metabolic interactions. Science 336: 1262–1267. doi: 10.1126/science.1223813 22674330
4. Cusi K, (2012) Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142: 711–725 e716. doi: 10.1053/j.gastro.2012.02.003 22326434
5. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, et al. (2011) Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9: 524–530. doi: 10.1016/j.cgh.2011.03.020 21440669
6. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, et al. (2013) Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58: 120–127. doi: 10.1002/hep.26319 23401313
7. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, et al. (2012) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 57: 601–609. doi: 10.1002/hep.26093 23055155
8. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, et al. (2012) Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62: 1787–1794. doi: 10.1136/gutjnl-2012-303816 23197411
9. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101: 15718–15723. doi: 10.1073/pnas.0407076101 15505215
10. Backhed F, Manchester JK, Semenkovich CF, Gordon JI, (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 104: 979–984. doi: 10.1073/pnas.0605374104 17210919
11. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, et al. (2013) The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 54: 2325–2340. doi: 10.1194/jlr.R036012 23821742
12. Zhu L, Baker RD, Baker SS (2014) Gut Microbiome and Non-alcoholic Fatty Liver Diseases. Pediatr Res. E-pub ahead of print.
13. Puertollano E, Kolida S, Yaqoob P, (2014) Biological significance of short-chain fatty acid metabolism by the intestinal microbiome. Curr Opin Clin Nutr Metab Care 17: 139–144. doi: 10.1097/MCO.0000000000000025 24389673
14. Newgard CB, (2012) Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 15: 606–614. doi: 10.1016/j.cmet.2012.01.024 22560213
15. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179–185. doi: 10.1038/nature10809 22297845
16. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, et al. (2008) Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 28: 1026–1033. doi: 10.1111/j.1478-3231.2008.01723.x 18397235
17. Ruiz AG, Casafont F, Crespo J, Cayon A, Mayorga M, et al. (2007) Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 17: 1374–1380. doi: 10.1007/s11695-007-9243-7 18000721
18. Alisi A, Manco M, Devito R, Piemonte F, Nobili V, (2010) Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 50: 645–649. doi: 10.1097/MPG.0b013e3181c7bdf1 20400911
19. Yuan J, Baker SS, Liu W, Alkhouri R, Baker RD, et al. (2014) Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J Gastroenterol Hepatol 29: 1292–1298. doi: 10.1111/jgh.12510 24372861
20. De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, et al. (2013) Dysbiosis contributes to fibrogenesis in the course of chronic liver injury. Hepatology 59: 1738–1749. doi: 10.1002/hep.26695 23959503
21. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499: 97–101. doi: 10.1038/nature12347 23803760
22. Calkin AC, Tontonoz P, (2012) Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 13: 213–224. doi: 10.1038/nrm3312 22414897
23. Chiang JY, (2013) Bile acid metabolism and signaling. Compr Physiol 3: 1191–1212. doi: 10.1002/cphy.c120023 23897684
24. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, et al. (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145: 574–582 e571. doi: 10.1053/j.gastro.2013.05.042 23727264
25. Schnabl B, Brenner DA, (2014) Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146: 1513–1524. doi: 10.1053/j.gastro.2014.01.020 24440671
26. Maher JJ, (2011) New insights from rodent models of fatty liver disease. Antioxid Redox Signal 15: 535–550. doi: 10.1089/ars.2010.3749 21126212
27. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, et al. (2006) Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 103: 12511–12516. doi: 10.1073/pnas.0601056103 16895997
28. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, et al. (2011) Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140: 976–986. doi: 10.1053/j.gastro.2010.11.049 21129376
29. Miele L, Cammarota G, Vero V, Racco S, Cefalo C, et al. (2012) Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Dig Liver Dis 44: 1032–1036. doi: 10.1016/j.dld.2012.08.005 22963909
30. Leonard J, Marshall JK, Moayyedi P, (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102: 2047–2056; quiz 2057. doi: 10.1111/j.1572-0241.2007.01275.x 17509031